Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: “Therapeutic options” and “Efalizumab”-Reference-Cited by-同舟云学术

Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: “Therapeutic options” and “Efalizumab”

Published:2009-11-12 Issue:1 Volume:8 Page:65-66
ISSN:1610-0379
Container-title:JDDG: Journal der Deutschen Dermatologischen Gesellschaft
language:en
Short-container-title:

Author:

Nast Alexander,Augustin Matthias,Boehncke Wolf-Henning,Klaus Joachim,Mrowietz Ulrich,Ockenfels Hans-Michael,Philipp Sandra,Reich Kristian,Rosenbach Thomas,Schlaeger Martin,Sebastian Michael,Sterry Wolfram,Streit Volker,Weisenseel Peter,Rzany Berthold

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1610-0387.2009.07312.x/fullpdf

Reference5 articles.

1. S3-Guidelines for the therapy of psoriasis vulgaris;Nast;J Dtsch Dermatol Ges,2007

2. http://www.emea.europa.eu/humandocs/Humans/EPAR/raptiva/raptiva.htm

3. EMEA setzt die Zulassung von Raptiva für die Therapie der Psoriasis aus;Prinz;Hautarzt,2009

4. Stellungnahme der DDG und des BVDD zur EMEA-Empfeh-lung über das Ruhen der Zulassung für Raptiva® (Efalizumab);Luger;J Dtsch Dermatol Ges.,2009

5. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study;Menter;Int J Dermatol.,2007

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncovering the Hidden Gems of Psoriasis Literature: An Neural Language Model-Assisted Interactive Web Tool;2023-03-16

2. Akne und Rosazea;Braun-Falco’s Dermatologie, Venerologie und Allergologie;2018

3. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study;British Journal of Dermatology;2017-02-02

4. Akne und Rosazea;Braun-Falco's Dermatologie, Venerologie und Allergologie;2017

5. Nichtablative fraktionierte Lasertherapie;Der Hautarzt;2015-08-08